A5051639380- Complement system in diseases
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- Hematopoietic Stem Cell Transplantation
- Respiratory viral infections research
- Immune Cell Function and Interaction
- Neonatal Respiratory Health Research
- Virus-based gene therapy research
- CAR-T cell therapy research
- Parvovirus B19 Infection Studies
- Reproductive System and Pregnancy
- Blood groups and transfusion
- Immune cells in cancer
- COVID-19 diagnosis using AI
- Mosquito-borne diseases and control
- Kawasaki Disease and Coronary Complications
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses
- Artificial Intelligence in Healthcare
Texas Children's Hospital
2023-2024
Baylor College of Medicine
2023-2024
Houston Methodist
2023-2024
Methodist Hospital
2023-2024
G. Papanikolaou General Hospital
2021-2023
There is an unmet need of models for early prediction morbidity and mortality Coronavirus disease-19 (COVID-19). We aimed to a) identify complement-related genetic variants associated with the clinical outcomes ICU hospitalization death, b) develop artificial neural network (ANN) predicting these c) validate whether are impaired complement phenotype. prospectively recruited consecutive adult patients Caucasian origin, hospitalized due COVID-19. Through targeted next-generation sequencing, we...
Respiratory syncytial virus (RSV)-associated viral infections are a major public health problem affecting the immunologically naïve/compromised populations. Given RSV-associated morbidity and limited treatment options, we sought to characterize cellular immune response RSV develop targeted T cell therapy for off-the-shelf administration immunocompromised individuals. Here report on immunological profiling, as well manufacturing, characterization antiviral properties of these RSV-targeted...
Reliable and sensitive characterization assays are important determinants of the successful clinical translation immunotherapies. For assessment cytolytic potential, chromium 51 ( Cr) release assay has long been considered gold standard for testing effector cells. However, attaining approvals to access use radioactive isotopes is becoming increasingly complex, while technical aspects [i.e. sensitivity, short (4-6 hours) duration] may lead suboptimal performance. This case with our ex vivo...
Regulatory T-cell (Treg) immunotherapy has emerged as a promising and highly effective strategy to combat graft-versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Both naturally occurring Treg induced populations have been successfully evaluated in trials illustrating the feasibility, safety, efficacy required for clinical translation. Using non-mobilized leukapheresis, we developed good manufacturing practice (GMP)-compatible product, termed iG-Tregs,...